Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
06
12
2022
accepted:
11
04
2023
medline:
19
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
HBV RNA in peripheral blood reflects HBV cccDNA transcriptional activity and may predict clinical outcomes. The prospective Melbourne HBV-STOP trial studied nucleot(s)ide analog discontinuation in HBeAg-negative non-cirrhotic participants with long-term virological suppression. Ninety-six weeks after stopping treatment, the proportion of participants with virological relapse (HBV DNA > 2000 IU/mL), biochemical relapse (ALT > 2 × ULN and HBV DNA > 2000 IU/mL), or hepatitis flare (ALT > 5 × ULN and HBV DNA > 2000 IU/mL) was 89%, 58%, and 38%, respectively. We evaluated the ability of serum HBV RNA levels to predict these outcomes. HBV RNA levels were measured using the Roche cobas 6800/8800 HBV RNA Investigational Assay. Sixty-five participants had baseline and longitudinal off-treatment specimens available for RNA testing. HBV RNA was detectable at baseline in 25% of participants and was associated with a higher risk of biochemical relapse (81% vs. 51%, p value 0.04) and hepatitis flare (63% vs. 31%, p value 0.04). Participants who had undetectable serum HBV RNA as well as HBsAg ≤ 100 IU/mL at baseline were less likely to experience virological relapse (4 of 9, 44%) than participants with detectable HBV RNA and HBsAg level > 100 IU/mL (15/15, 100%; p value 0.0009). Off-treatment levels of HBV RNA were correlated with HBV DNA and were associated with the risk of hepatitis flare. Serum HBV RNA may be a useful biomarker for guiding clinical decision-making before stopping nucleot(s)ide analog therapy. Baseline HBV RNA and HBsAg levels are associated with the risk of clinical relapse, hepatitis flare, and disease remission off-treatment.
Sections du résumé
BACKGROUND AND AIMS
HBV RNA in peripheral blood reflects HBV cccDNA transcriptional activity and may predict clinical outcomes. The prospective Melbourne HBV-STOP trial studied nucleot(s)ide analog discontinuation in HBeAg-negative non-cirrhotic participants with long-term virological suppression. Ninety-six weeks after stopping treatment, the proportion of participants with virological relapse (HBV DNA > 2000 IU/mL), biochemical relapse (ALT > 2 × ULN and HBV DNA > 2000 IU/mL), or hepatitis flare (ALT > 5 × ULN and HBV DNA > 2000 IU/mL) was 89%, 58%, and 38%, respectively. We evaluated the ability of serum HBV RNA levels to predict these outcomes.
APPROACH RESULTS
HBV RNA levels were measured using the Roche cobas 6800/8800 HBV RNA Investigational Assay. Sixty-five participants had baseline and longitudinal off-treatment specimens available for RNA testing. HBV RNA was detectable at baseline in 25% of participants and was associated with a higher risk of biochemical relapse (81% vs. 51%, p value 0.04) and hepatitis flare (63% vs. 31%, p value 0.04). Participants who had undetectable serum HBV RNA as well as HBsAg ≤ 100 IU/mL at baseline were less likely to experience virological relapse (4 of 9, 44%) than participants with detectable HBV RNA and HBsAg level > 100 IU/mL (15/15, 100%; p value 0.0009). Off-treatment levels of HBV RNA were correlated with HBV DNA and were associated with the risk of hepatitis flare.
CONCLUSIONS
Serum HBV RNA may be a useful biomarker for guiding clinical decision-making before stopping nucleot(s)ide analog therapy. Baseline HBV RNA and HBsAg levels are associated with the risk of clinical relapse, hepatitis flare, and disease remission off-treatment.
Identifiants
pubmed: 37459199
doi: 10.1097/HC9.0000000000000188
pii: 02009842-202308010-00004
pmc: PMC10351945
pii:
doi:
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
Hepatitis B e Antigens
0
Hepatitis B Surface Antigens
0
Nucleosides
0
RNA
63231-63-0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
PLoS One. 2014 Oct 22;9(10):e110442
pubmed: 25337821
Hepatology. 2016 Dec;64(6):2246-2249
pubmed: 27639252
J Hepatol. 2022 May;76(5):1042-1050
pubmed: 35092743
Hepatology. 2015 Jan;61(1):66-76
pubmed: 25132147
Hepatol Int. 2021 Aug;15(4):833-851
pubmed: 34297329
Gut. 2015 Apr;64(4):667-72
pubmed: 24833635
Semin Immunopathol. 2020 Apr;42(2):173-185
pubmed: 32185454
Hepatology. 2018 Sep;68(3):839-847
pubmed: 29514389
Aliment Pharmacol Ther. 2022 Jul;56(2):310-320
pubmed: 35521992
Intervirology. 2011;54(6):316-25
pubmed: 21242658
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1813-1820.e1
pubmed: 27404969
J Clin Virol. 2022 Jun;150-151:105150
pubmed: 35427860
Clin Gastroenterol Hepatol. 2020 Mar;18(3):719-727.e7
pubmed: 31362119
Nature. 2016 Mar 17;531(7594):386-9
pubmed: 26983541
Hepatology. 2019 Sep;70(3):1045-1055
pubmed: 30561829
Infect Drug Resist. 2020 Oct 29;13:3873-3886
pubmed: 33149632
Nat Rev Gastroenterol Hepatol. 2022 Nov;19(11):727-745
pubmed: 35859026
Cell Mol Gastroenterol Hepatol. 2019;7(2):297-312
pubmed: 30704981
Gut. 2021 Apr;70(4):775-783
pubmed: 32759300
Biometrika. 1951 Jun;38(1-2):141-9
pubmed: 14848119
Gut. 2019 Dec;68(12):2206-2213
pubmed: 31462554
Virol J. 2022 Jan 29;19(1):22
pubmed: 35093105
Hepatology. 2017 Dec;66(6):2066-2077
pubmed: 28833361
Hepatology. 2018 Dec;68(6):2106-2117
pubmed: 29734472
J Hepatol. 2017 Feb;66(2):460-462
pubmed: 27826059
J Gastroenterol. 2013 Oct;48(10):1188-204
pubmed: 23397114
Mol Med Rep. 2016 Jan;13(1):301-8
pubmed: 26573490
Hepatology. 2020 Jul;72(1):42-57
pubmed: 31701544
Hepatology. 2018 Aug;68(2):425-434
pubmed: 29108132
J Med Virol. 2022 Dec;94(12):6116-6121
pubmed: 35982504
Microbiol Spectr. 2022 Apr 27;10(2):e0214921
pubmed: 35377229
Am J Gastroenterol. 2016 Sep;111(9):1286-94
pubmed: 27045923
Hepatology. 2019 Oct;70(4):1488-1489
pubmed: 30793771
Gastroenterology. 2012 Sep;143(3):629-636.e1
pubmed: 22659218
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19975-9
pubmed: 19906987
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Gastroenterology. 2022 Mar;162(3):757-771.e4
pubmed: 34762906
Hepatology. 2022 Nov;76(5):1520-1530
pubmed: 35342969
Hepatol Commun. 2021 Oct;5(10):1632-1648
pubmed: 34558833
Gut. 2022 Aug;71(8):1629-1641
pubmed: 34493592
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Liver Int. 2019 Oct;39(10):1868-1875
pubmed: 31136052
Dig Dis Sci. 2018 Dec;63(12):3487-3497
pubmed: 30136045
Hepatology. 2019 Apr;69(4):1816-1827
pubmed: 30362148
Clin Infect Dis. 2021 Jan 27;72(2):202-211
pubmed: 31912157
J Hepatol. 2017 Nov;67(5):918-924
pubmed: 28736139